Annovis Bio, Inc. disclosed new biomarker data from its Phase 3 early Parkinson’s disease study (NCT05357989) that shows patients with amyloid co‑pathology experience accelerated cognitive decline, but treatment with Buntanetap halted and reversed that decline.
The study measured plasma pTau217, total tau, and brain‑derived tau; all three biomarkers were reduced in the Buntanetap group, and the reductions correlated with measurable cognitive improvement. Approximately 25 % of the study participants carried amyloid co‑pathology, underscoring the relevance of the findings to a sizable subset of Parkinson’s patients.
These results broaden the potential treatment population to include Parkinson’s patients with Alzheimer’s pathology, a group that has historically been difficult to treat. The data also reinforce Buntanetap’s multi‑target mechanism of action, which aims to reduce several neurotoxic proteins simultaneously, and could accelerate the company’s regulatory path for the drug in Parkinson’s disease.
Annovis has faced financial challenges, reporting negative earnings and high stock volatility in recent quarters. The company’s Q3 2025 financial results were released on November 12, 2025, and while the new biomarker data adds scientific momentum, it does not alter the current financial outlook or guidance, which remain unchanged.
Management emphasized the significance of the findings. Senior VP Cheng Fang said the data are the first of their kind in Parkinson’s patients with amyloid co‑pathology and position Buntanetap as a promising therapeutic candidate across multiple neurodegenerative diseases.
The full biomarker data set will be presented at the CTAD conference in San Diego from December 1‑4, 2025, where the company will provide additional detail and engage with the scientific community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.